[ad_1]
Prothena Co. plc (NASDAQ:PRTA – Get Ranking) CFO Tran Nguyen offered 10,000 shares of the agency’s inventory in a transaction on Wednesday, August 24th. The shares had been offered at a median worth of $30.17, for a complete worth of $301,700.00. Following the completion of the transaction, the chief monetary officer now owns 3,200 shares within the firm, valued at roughly $96,544. The sale was disclosed in a doc filed with the SEC, which is accessible via this hyperlink.
Tran Nguyen additionally not too long ago made the next commerce(s):
- On Wednesday, July 20th, Tran Nguyen offered 42,120 shares of Prothena inventory. The shares had been offered at a median worth of $32.49, for a complete worth of $1,368,478.80.
- On Friday, July 22nd, Tran Nguyen offered 7,320 shares of Prothena inventory. The shares had been offered at a median worth of $32.55, for a complete worth of $238,266.00.
Prothena Inventory Efficiency
Shares of NASDAQ PRTA traded down $2.30 throughout buying and selling on Friday, hitting $27.98. 389,258 shares of the corporate had been exchanged, in comparison with its common quantity of 401,028. Prothena Co. plc has a 12-month low of $21.06 and a 12-month excessive of $79.75. The corporate has a fifty day shifting common worth of $30.09 and a 200-day shifting common worth of $31.27. The agency has a market capitalization of $1.31 billion, a PE ratio of -116.58 and a beta of 1.31.
Prothena (NASDAQ:PRTA – Get Ranking) final posted its quarterly earnings outcomes on Monday, August eighth. The biotechnology firm reported ($0.88) EPS for the quarter, lacking the consensus estimate of ($0.51) by ($0.37). Prothena had a destructive return on fairness of 0.33% and a destructive internet margin of 1.03%. The corporate had income of $1.31 million for the quarter, in comparison with analysts’ expectations of $20.12 million. Analysis analysts anticipate that Prothena Co. plc will put up -2.57 earnings per share for the present fiscal 12 months.
Wall Road Analysts Forecast Development
Individually, JMP Securities decreased their worth goal on Prothena from $77.00 to $50.00 and set a “market outperform” score on the inventory in a report on Wednesday, Might 25th. One funding analyst has rated the inventory with a maintain score and 5 have issued a purchase score to the inventory. In line with MarketBeat.com, the inventory at present has a consensus score of “Average Purchase” and a consensus goal worth of $70.33.
Institutional Inflows and Outflows
A number of institutional traders have not too long ago modified their holdings of PRTA. FMR LLC elevated its place in shares of Prothena by 9.3% through the 2nd quarter. FMR LLC now owns 2,925,398 shares of the biotechnology firm’s inventory price $79,425,000 after buying an extra 249,784 shares over the past quarter. State Road Corp elevated its place in shares of Prothena by 20.0% through the 1st quarter. State Road Corp now owns 2,367,583 shares of the biotechnology firm’s inventory price $86,583,000 after buying an extra 394,633 shares over the past quarter. First Mild Asset Administration LLC elevated its place in shares of Prothena by 5.4% through the 2nd quarter. First Mild Asset Administration LLC now owns 1,938,183 shares of the biotechnology firm’s inventory price $52,622,000 after buying an extra 99,635 shares over the past quarter. Dimensional Fund Advisors LP elevated its place in shares of Prothena by 0.4% through the 1st quarter. Dimensional Fund Advisors LP now owns 1,505,156 shares of the biotechnology firm’s inventory price $55,044,000 after buying an extra 6,619 shares over the past quarter. Lastly, Renaissance Applied sciences LLC elevated its place in shares of Prothena by 74.0% through the 2nd quarter. Renaissance Applied sciences LLC now owns 686,000 shares of the biotechnology firm’s inventory price $18,625,000 after buying an extra 291,800 shares over the past quarter. Hedge funds and different institutional traders personal 92.64% of the corporate’s inventory.
Prothena Firm Profile
Prothena Company plc, a late-stage scientific firm, focuses on discovery and growth of novel therapies for life-threatening illnesses in the USA. The corporate is concerned in creating Birtamimab, an investigational humanized antibody that’s in Part III scientific trial for the therapy of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Part IIb scientific trial for the therapy of Parkinson’s illness; PRX004 that accomplished Part I scientific trial for the therapy of Transthyretin amyloidosis; and PRX005, which is in Part I scientific trial for the therapy of Alzheimer’s illness.
Additional Studying
This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Prothena, you will wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Prothena wasn’t on the checklist.
Whereas Prothena at present has a “Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.
[ad_2]
Supply hyperlink